Sridharan Gururangan, MRCP

Related Content

Services

• Brain Tumors
• Neurological Disorders
• Pediatric Cancer

Department / Division:
Surgery / Neurosurgery

Address:
DUMC 3624
Durham, NC 27710

Appointment Telephone:
(919) 668-6288

Office Telephone:
(919) 684-3506

Fax Telephone:
(919) 668-2485

• M.B.B.S., Stanley Medical College, India, 1982

• Pediatrics, Lebonheur Children's Medical Center, Tennessee, 1992-1993

• St. Jude Children's Research Hospital, Tennessee, 1991-1992
• Memorial Sloan-Kettering Cancer Center, New York, 1996-1999

• M.R.C.P., Pediatrics, Royal College of Physicians of England, 1988

Clinical Interests:
Interested in developing innovative phase I and II trials in the treatment of children with recurrent brain tumors

Research Interests:
Dr. Gururangan is a member of the Duke University Medical Center Pediatric Neuro-Oncology program. His current research interest focuses on finding novel chemotheapeutic strategies for the treatment of children and young adults with brain tumors. Since beginning his tenure at the Brain Tumor Center at Duke, he has written four clinical protocols. These protocols have incorporated some of the important laboratory findings obtained from the laboratory of Dr. Henry Friedman. These protocols are designed to improve survival of children and young adults with brain stem gliomas and other malignant brain tumors. These protocols will be administered locally and in other regional clinics that share care with the brain tumor center. He is also the co-principal investigator on two protocols using oral Temzolomide in children and young adults with recurrent low-grade gliomas and newly diagnosed malignant brain tumors. Another protocol using the same drug, is studying the efficacy of this agent used in high-doses with stem cell rescue in high risk malignant brain tumors.  Dr. Gururangan is a member of the Pediatric Oncology Group and is a principal investigator on an upcoming POG phase II study of O6 Benzylguanine plus BCNU in children with recurrent malignant gliomas previously resistant to nitrosoureas.  This study will explore the novel mechanism of subverting tumor resistance to nitrosureas using O6 benzylguanine.  Dr. Gururangan is also a member of the Pediatric Brain Tumor Consortium and has submitted a Letter of Intent (LOI) through the consortium to the Cancer Therapy Evaluation Program for studying the toxicity and pharmacokinetics of  intrathecal Spartject(Busulfan in children with resistant leptomeningeal disease from recurrent brain tumors, acute lymphoblastic leukemia, and lymphoma. As a member of these two groups he is in a strategic position to evaluate novel therapeutic modalities in patients with brain tumors.

Representative Publications:
Gururangan S, Sposto R, Cairo MS, Meadows AT, Finlay JL. Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study. J Clin Oncol. 2000 May;18(10):2017-25. (2000) Abstract

Gururangan S, Dunkel IJ, Goldman S, Garvin J, Rosenblum M, Boyett J, and Finlay J. Myeloablative chemotherapy followed by autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998; 16 (7): 2486-2493 (1998)

Gururangan S, Gardner S, and Finlay JL. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for malignant tumors of the central nervous system. Clinical Bone Marrow and Stem Cell Transplantation, 2nd edition, Kerry Atkinson ed., Cambridge University Press, (in press 2000) (2000)

Gururangan S, Cavazos CM, Ashley D, Herndon JE 2nd, Bruggers CS, Moghrabi A, Scarcella DL, Watral M, Tourt-Uhlig S, Reardon D, Friedman HS. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol. 2002 Jul 1;20(13):2951-8. (2002) Abstract

Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, McLendon RE, Friedman AH, Tourt-Uhlig S, Miller LL, Friedman HS. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-oncol. 2002 Apr;4(2):102-8. (2002) Abstract

Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-oncol. 2001 Oct;3(4):246-50. (2001) Abstract

Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002 May 1;20(9):2277-83. (2002) Abstract

Gururangan S, McFarland JG, Cines DB, Skupski D, Bussel JB. BRa (HPA-5b) incompatibility may cause thrombocytopenia in neonates of mothers with immune thrombocytopenic purpura. J Pediatr Hematol Oncol. 1998 May-Jun;20(3):202-6. (1998) Abstract

Gururangan S, Marina NM, Luo X, Parham DM, Tzen CY, Greenwald CA, Rao BN, Kun LE, Meyer WH. Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor with Ewing's-directed therapy. J Pediatr Hematol Oncol. 1998 Jan-Feb;20(1):55-61. (1998) Abstract